2008
DOI: 10.1080/01635580801956501
|View full text |Cite
|
Sign up to set email alerts
|

Glutamine Affects Glutathione Recycling Enzymes in a DMBA-Induced Breast Cancer Model

Abstract: Malignancy depletes host glutathione (GSH) levels to increase treatment-related toxicity and increases itself to resist the treatments. Our previous studies have shown that dietary glutamine (GLN) prevented 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors through enhancing gut GSH release and reducing tumor GSH level. In addition, GSH synthesis, metabolism, and recycling are accomplished in gamma-glutamyl cycle. We hypothesized that the GLN prevention might be through a differential regulation of t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
3
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 43 publications
(51 reference statements)
1
3
0
Order By: Relevance
“…Thus, in experimental breast cancer, dietary glutamine could paradoxically promote the process of apoptosis. This was reported to be the result of glutathione downregulation [140,141]. These results illustrate the complex regulation exerted by glutamine on transcription factor such as c-myc, i.e.…”
Section: Transcription Factors Involved In the Regulatory Role Of Glusupporting
confidence: 56%
“…Thus, in experimental breast cancer, dietary glutamine could paradoxically promote the process of apoptosis. This was reported to be the result of glutathione downregulation [140,141]. These results illustrate the complex regulation exerted by glutamine on transcription factor such as c-myc, i.e.…”
Section: Transcription Factors Involved In the Regulatory Role Of Glusupporting
confidence: 56%
“…The paradoxical effect of Gln on GSH metabolism in tumor and host tissues may be a result of the relatively more acidic intracellular environment of tumors compared with normal structures, thus inactivating the pH-sensitive enzyme 5-oxoprolinase, which catalyzes the formation of g-glutamyl-Gln dipeptide, an immediate precursor of GSH in the g-glutamyl cycle to glutamate (35). Our data showed that Gln downregulated several enzymes of the g-glutamyl cycle, including 5-oxoprolinase and glutaminase in tumor, but upregulated them in normal tissues (36). The differential effect of Gln on GSH recycling of normal tissues and tumors was associated with a reduction of tumor growth in breast cancer model (19).…”
Section: Discussionmentioning
confidence: 87%
“…In implantable sarcoma and breast carcinoma rat models, it was demonstrated that daily oral administration of glutamine results in a 40 % decrease in tumour growth compared to isonitrogenous-fed controls ( 26 ) . Moreover, the data of some studies allow suggestion that dietary supplemental glutamine could be used in the clinical practice to increase the therapeutic index of cancer treatments by protecting normal tissues from, and sensitising tumour cells to, chemotherapy and radiation-related injury ( 27 , 28 ) . Enhancing the antioxidant status of the body and activation of apoptosis exerts chemopreventive effects of glutamine ( 29 ) .…”
Section: Discussionmentioning
confidence: 99%